敷尔佳：“重组Ⅲ型人源化胶原蛋白冻干纤维”已完成临床试验并取得临床试验总结报告

Core Viewpoint - The company has completed clinical trials for its product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" and is now ready to submit registration application materials, marking a significant step in expanding its presence in the medical aesthetics market and enriching its product line [1] Group 1 - The product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" is the company's first shallow injection filler product [1] - The completion of clinical trials and the acquisition of the clinical trial summary report are crucial milestones for the company [1] - This development is expected to have important implications for the company's expansion into the medical aesthetics clinic market [1]